Abstract CT017: First-in-human PET imaging with the PD-L1 antibody 89 Zr-atezolizumab

Autor: Bensch, Frederike, Veen, Elly van der, Jorritsma, Annelies, Hooge, Marjolijn Lub-de, Boellaard, Ronald, Oosting, Sjoukje, Schröder, Carolien, Hiltermann, Jeroen, Wekken, Anthonie van der, Groen, Harry, Fine, Bernard, McKnight, Nathan, Bohorquez, Sandra Sanabria, Williams, Simon, Veronese, Luisa, Mancao, Christoph, Brouwers, Adrienne H., Vries, Elisabeth de

Publikováno v: Bensch, F, Veen, E V D, Jorritsma, A, Hooge, M L, Boellaard, R, Oosting, S, Schröder, C, Hiltermann, J, Wekken, A V D, Groen, H, Fine, B, McKnight, N, Bohorquez, S S, Williams, S, Veronese, L, Mancao, C, Brouwers, A H & Vries, E D 2017, Abstract CT017: First-in-human PET imaging with the PD-L1 antibody 89 Zr-atezolizumab . in Cancer Research . Cancer Research, vol. 77, pp. CT017-CT017 . https://doi.org/10.1158/1538-7445.AM2017-CT017

Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Background: Programmed death-ligand 1 (PD-L1) expression has been associated with response to PD-1/PD-L1 inhibition, but responses are also seen in patients with PD-L1 negative tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10172::2fb5987218b7bf23b780e8e92ff54aa5
https://research.vumc.nl/en/publications/8e4da63d-2004-49b0-b3c6-749d74fac562